Der-Shiun Wang1,2, Chih-Hsiang Yu3, Chien-Yu Lin4, Ya-Hsuan Chang4, Kai-Hsin Lin5,6, Dong-Tsamn Lin5,6,7, Shiann-Tarng Jou5,6, Meng-Yao Lu5,6, Hsiu-Hao Chang5,6, Shu-Wha Lin3, Hsuan-Yu Chen4, Yung-Li Yang8,9,10. 1. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. 2. Department of Pediatrics, Tri-service General Hospital, National Defense Medical Center, Taipei, Taiwan. 3. Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan. 4. Institute of Statistical Science, Academia Sinica, Taipei, Taiwan. 5. Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan. 6. Department of Pediatrics, College of Medicine, National Taiwan University, Taipei, Taiwan. 7. Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan. 8. Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan. yangyl92@ntu.edu.tw. 9. Department of Pediatrics, College of Medicine, National Taiwan University, Taipei, Taiwan. yangyl92@ntu.edu.tw. 10. Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan. yangyl92@ntu.edu.tw.
Abstract
BACKGROUND: Mercaptopurine-induced neutropenia can interrupt chemotherapy and expose patients to infection during childhood acute lymphoblastic leukemia (ALL) treatment. Previously, six candidate gene variants associated with mercaptopurine intolerance were reported. Herein, we investigated the association between the mean tolerable dose of mercaptopurine and these genetic variants in Taiwanese patients. METHODS: In total, 294 children with ALL were treated at the National Taiwan University Hospital from April 1997 to December 2017. Germline variants were analyzed for NUDT15, SUCLA2, TPMT, ITPA, PACSIN2, and MRP4. Mean daily tolerable doses of mercaptopurine in the continuation phase of treatment were correlated with these genetic variants. RESULTS: Mercaptopurine intolerance was significantly associated with polymorphisms in NUDT15 (P value < 0.0001). Patients with SUCLA2 variants received lower mercaptopurine doses (P value = 0.0119). The mean mercaptopurine doses did not differ among patients with TPMT, ITPA, MRP4, and PACSIN2 polymorphisms (P value = 0.9461, 0.5818, and 0.7951, respectively). After multivariable linear regression analysis, only NUDT15 variants retained their clinically significant correlation with mercaptopurine intolerance (P value < 0.0001). CONCLUSION: In this cohort, the major genetic determinant of mercaptopurine intolerance was NUDT15 in Taiwanese patients. IMPACT: NUDT15 causes mercaptopurine intolerance in children with ALL. The NUDT15 variant is a stronger predictor of mercaptopurine intolerance than TPMT in a Taiwanese cohort. This finding is similar with studies performed on Asian populations rather than Caucasians. Pre-emptive genotyping of the patients' NUDT15 before administering mercaptopurine may be more helpful than genotyping TPMT in Asians.
BACKGROUND:Mercaptopurine-induced neutropenia can interrupt chemotherapy and expose patients to infection during childhood acute lymphoblastic leukemia (ALL) treatment. Previously, six candidate gene variants associated with mercaptopurine intolerance were reported. Herein, we investigated the association between the mean tolerable dose of mercaptopurine and these genetic variants in Taiwanese patients. METHODS: In total, 294 children with ALL were treated at the National Taiwan University Hospital from April 1997 to December 2017. Germline variants were analyzed for NUDT15, SUCLA2, TPMT, ITPA, PACSIN2, and MRP4. Mean daily tolerable doses of mercaptopurine in the continuation phase of treatment were correlated with these genetic variants. RESULTS:Mercaptopurine intolerance was significantly associated with polymorphisms in NUDT15 (P value < 0.0001). Patients with SUCLA2 variants received lower mercaptopurine doses (P value = 0.0119). The mean mercaptopurine doses did not differ among patients with TPMT, ITPA, MRP4, and PACSIN2 polymorphisms (P value = 0.9461, 0.5818, and 0.7951, respectively). After multivariable linear regression analysis, only NUDT15 variants retained their clinically significant correlation with mercaptopurine intolerance (P value < 0.0001). CONCLUSION: In this cohort, the major genetic determinant of mercaptopurine intolerance was NUDT15 in Taiwanese patients. IMPACT: NUDT15 causes mercaptopurine intolerance in children with ALL. The NUDT15 variant is a stronger predictor of mercaptopurine intolerance than TPMT in a Taiwanese cohort. This finding is similar with studies performed on Asian populations rather than Caucasians. Pre-emptive genotyping of the patients' NUDT15 before administering mercaptopurine may be more helpful than genotyping TPMT in Asians.
Authors: Chengcheng Liu; Laura J Janke; Jun J Yang; William E Evans; John D Schuetz; Mary V Relling Journal: Cancer Chemother Pharmacol Date: 2017-06-16 Impact factor: 3.333
Authors: Mary V Relling; Matthias Schwab; Michelle Whirl-Carrillo; Guilherme Suarez-Kurtz; Ching-Hon Pui; Charles M Stein; Ann M Moyer; William E Evans; Teri E Klein; Federico Guillermo Antillon-Klussmann; Kelly E Caudle; Motohiro Kato; Allen E J Yeoh; Kjeld Schmiegelow; Jun J Yang Journal: Clin Pharmacol Ther Date: 2019-01-20 Impact factor: 6.875
Authors: D C Liang; I J Hung; C P Yang; K H Lin; J S Chen; T C Hsiao; T T Chang; C H Pui; C H Lee; K S Lin Journal: Leukemia Date: 1999-02 Impact factor: 11.528
Authors: Tina Gerbek; Maria Ebbesen; Jacob Nersting; Thomas L Frandsen; Malin Lindqvist Appell; Kjeld Schmiegelow Journal: Cancer Chemother Pharmacol Date: 2018-02-01 Impact factor: 3.333
Authors: Q S Hao; Z Wang; Q Y Fang; X Y Gong; K Q Liu; Y Li; H Wei; Y Wang; Q H Li; M Wang; Z Tian; J X Wang; Y C Mi Journal: Zhonghua Xue Ye Xue Za Zhi Date: 2021-11-14